Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

RNA profiles of MOLM-13 cells treated with FLT3 inhibitor in the presence of conditioned media of bone marrow stromal cells

ABSTRACT: RNA-seq analysis of MOLM-13 cells to compare the gene expression profiles post FLT3 inhibition and/or ATM inhibition in the presence or absence of conditioned media of bone marrow stromal cell HS-5

ORGANISM(S): Homo sapiens

PROVIDER: GSE202229 | GEO | 2022/10/19

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

RNA profiles of polysomes from MOLM-13 cells treated with FLT3 inhibitor and/or mTOR inhibitor in the presence of conditioned media of bone marrow stomal cells

Project description:RNA-seq analysis of MOLM13 cells to compare mRNAs enriched in heavy polysomes post FLT3 inhibition and/or mTOR inhibition in the presence or absence of conditioned media of bone marrow stromal cells HS-5 (hBMSC-CM)

2022-10-19 | GSE202227 | GEO

RNA profiles of MOLM-13 cells treated with FLT3 inhibitor in the presence of conditioned media of bone marrow stromal cells

Project description:RNA profiles of MOLM-13 cells treated with FLT3 inhibitor in the presence of conditioned media of bone marrow stromal cells

| PRJNA835089 | ENA

Phosphoproteome Analysis Reveals Differential Mode of Action of Sorafenib in Wildtype and Mutated FLT3 AML Cells

Project description:Constitutively activating internal tandem duplication (ITD) alterations of the receptor tyrosine kinase FLT3 (Fms-like tyrosine kinase 3) are common in acute myeloid leukemia (AML) and classifies FLT3 as an attractive therapeutic target. So far, application of FLT3 small molecule inhibitors such as Sorafenib has resulted only in partial and transient clinical responses in FLT3-ITD+ patients. Only recently, a prolonged event-free survival has been observed in AML patients who were treated with Sorafenib in addition to standard therapy. Here, we studied the Sorafenib effect on proliferation in a panel of 13 FLT3-ITD- and FLT3-ITD+ AML cell lines. Sorafenib IC50 values ranged from 0.001 to 5.6 µM, whereas FLT3-ITD+ cells (MOLM-13, MV4;11) were found more sensitive to Sorafenib than FLT3-ITD- cells. However, we identified two FLT3-ITD- cell lines (MONO-MAC-1 and OCI-AML-2) which were also Sorafenib sensitive. Phosphoproteome analyses revealed that the affected pathways differed in Sorafenib sensitive FLT3-ITD- and FLT3-ITD+ cells. In MV4;11 cells Sorafenib suppressed mTOR signalling by inhibiting direct inhibition of FLT3. In MONO-MAC-1 cells Sorafenib inhibited the MEK/ERK pathway by inhibition of the RET tyrosine kinase. These data suggest that the FLT3 status in AML patients might not be the only predictive factor for a response to Sorafenib.

2017-05-02 | PXD004442 | Pride

ChIP-seq analysis of HA-KAT6A in MOLM-13 AML cells

Project description:ChIP-seq analysis of MOLM-13 human leukemia cells with overexpression of WT KAT6A with HA tag.

2021-10-20 | GSE157039 | GEO

RNA-seq analysis of Molm-13 cell with GADD45g overexpressed

Project description:The growth arrest and DNA-damage induced 45 gamma (GADD45g) is rapidly induced by various physiological and environmental stresses associated with growth arrest. GADD45g has been observed implicated in cell survival, apoptosis, senescence, cell cycle regulation and DNA repair in a variety of human solid tumor types, acting as either tumor promoter or tumor suppressor. To date, the role of GADD45g in hematopoietic malignancies remains completely unknown. Here, we transduced Molm-13 cells with lentiviral vectors expressing doxycycline-inducible GADD45g. Molm-13 cells with dox administration or not were collected for RNA-seq.

2023-06-22 | GSE152932 | GEO

Transcriptional profiling of MOLM-13 AML cells following KAT6A CRISPR targeting

Project description:RNA-seq analysis of MOLM-13 human leukemia cells transduced with lentivirus containing CRISPR-Cas9 EV or sgKAT6A for 5 days

2021-10-20 | GSE156948 | GEO

Expression changes after Inhibition of AHD in Molm-13 cells

Project description:Expression changes after Inhibition of AHD in Molm-13 cells

| PRJNA636784 | ENA

RNA-seq of MOLM-13 acute myeloid leukemia cell line treated with FIDAS-5

Project description:MOLM-13 acute myeloid leukemia cells were treated with 3 µM FIDAS-5 methionine S-adenosyltransferase 2A (MAT2A) inhibitor or 0.1% DMSO as control for 48 hours

2023-04-22 | E-MTAB-12847 | biostudies-arrayexpress

RNA profiles of polysomes from MOLM-13 cells treated with FLT3 inhibitor and/or mTOR inhibitor in the presence of conditioned media of bone marrow stomal cells

Project description:RNA profiles of polysomes from MOLM-13 cells treated with FLT3 inhibitor and/or mTOR inhibitor in the presence of conditioned media of bone marrow stomal cells

| PRJNA835090 | ENA

Study of gene expression following Pim2 knockdown in FLT3-ITD-positive acute myeloid leukemia

Project description:The objective of the sudy is to explore the biological pathways controlled by Pim2 in FLT3-ITD positive AML We used microarrays to investigate gene expression in the MOLM-14 AML cell line in which Pim2 knockdown was induced by RNA interference (doxycycline-inducible shRNA)

2018-02-14 | GSE94870 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data